🕒 Last update: loading…16/11/2026

Stock Beam Therapeutics Inc. BEAM

Beam Therapeutics Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: -2.39%

Price change 2021 → 2022: -50.92%

Price change 2022 → 2023: -30.40%

Price change 2023 → 2024: -8.89%

Price change 2024 → 2025: 11.77%

Price change 2025 → 2026: -1.77%

Price change 2026 (year to date): 0.33%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.24

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -8.28

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 28.19% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Beam Therapeutics Inc.–0.24–🔒
Clover Health Investments, Corp.113.00.00+31.6 %–
iRhythm Technologies, Inc.–4.79+38.2 %–
Pediatrix Medical Group, Inc.14.00.76+2.1 %–
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Beam Therapeutics Inc. over the latest fiscal years.

Revenue
140 m USD
fiscal year 2025
Net income
-80.0 m USD
fiscal year 2025
Net margin
-57.2 %
fiscal year 2025
Average annual growth
+466.3 %
Revenue growth over 5 years
Market cap
2.4 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202024,000-195 m-810,800.0 %n/a
202151.8 m-371 m-714.9 %+215,916.7 %
202260.9 m-289 m-474.5 %+17.5 %
2023378 m-133 m-35.1 %+520.0 %
202463.5 m-377 m-593.1 %-83.2 %
2025140 m-80.0 m-57.2 %+120.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Beam Therapeutics Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
3.46
safe zone (above 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.36 x
net cash
Fiscal year20212022202320242025
Cash and investments966 m1.1 bn1.2 bn851 m1.2 bn
Total Debt148 m179 m173 m161 m294 m
Net Debt-412 m-53.8 m-263 m-121 m-1.1 m
Equity827 m733 m981 m734 m1.2 bn
Total assets1.5 bn1.3 bn1.5 bn1.1 bn1.5 bn
Operating cash flow-66.3 m22.5 m-149 m-347 m-345 m
Investments (capex)46.8 m49.0 m33.7 m8.9 m14.9 m
Free cash-flow-113 m-26.4 m-183 m-356 m-360 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-24.03 x
Price / book value2.64 x
Return on Equity (ROE)-9.7 %
Return on Invested Capital (ROIC)-32.6 %
Net margin-73.0 %
Debt / equity0.26 x
Current ratio13.00 x
Free cash-flow yield-16.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Beam Therapeutics Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Beam Therapeutics Inc.2.4 bnn/a-57.2 %
CRISPR Therapeutics AG CRSP4.1 bnn/a-16,569.8 %
Intellia Therapeutics, Inc. NTLA1.4 bnn/a-609.9 %
Editas Medicine, Inc. EDIT335 mn/a-395.0 %
Precision BioSciences, Inc. DTIL211 mn/a-133.4 %
Allogene Therapeutics, Inc. ALLO291 mn/a0.0 %
Fate Therapeutics, Inc. FATE149 mn/a-2,051.1 %
Caribou Biosciences, Inc. CRBU39.1 mn/a-1,327.4 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Beam Therapeutics Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
28 analysts

Breakdown of ratings

strong buy 0buy 19hold 8sell 1strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Beam Therapeutics Inc.

Free float
85.1 %
share of freely traded shares
Large funds tracked
24
hold the stock as of 2026Q2
Executives (insiders)
0 / 4
0 purchases, 4 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Fidelity12.6 m433 m0.0 %+1.3 %2026Q2
State Street11.7 m400 m0.0 %+104.5 %2026Q2
ARK Investment Management10.2 m351 m2.3 %-15.6 %2026Q2
BlackRock9.0 m309 m0.0 %+6.0 %2026Q2
Vanguard Group9.2 m255 m0.0 %-0.6 %2025Q4
T. Rowe Price3.4 m117 m0.0 %+25.9 %2026Q2
Geode Capital Management2.6 m89.1 m0.0 %+7.4 %2026Q2
Morgan Stanley2.0 m67.0 m0.0 %+201.0 %2026Q2

Latest insider transactions

DatePersonSideAmount
16/10/2026Evans John M.sale599,595 USD
15/10/2026Evans John M.sale589,150 USD
01/10/2026Cavanagh Bethany Jsale4,565 USD
27/07/2026Simon Amysale429,037 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 06/02/2020
ISIN code
US07373V1052
Workforce
393
full-time employees
Chief executive
John M. Evans

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Beam Therapeutics Inc.

What is the Beam Therapeutics Inc. share price?

Latest recorded price: 22.83 USD on 13/11/2026, for a market cap of 2.4 bn USD.

What is the revenue of Beam Therapeutics Inc.?

140 m USD for fiscal year 2025, with net income of -80.0 m USD (net margin -57.2 %).

What do analysts say about Beam Therapeutics Inc.?

Out of 28 analysts: 19 buy or strong buy, 8 hold, 1 sell or strong sell.

Is Beam Therapeutics Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US07373V1052).

How many employees does Beam Therapeutics Inc. have?

393 full-time employees according to the latest published profile.

Who runs Beam Therapeutics Inc.?

John M. Evans is the company's chief executive.

Which large funds own Beam Therapeutics Inc.?

As of 2026Q2, among the large funds tracked: Fidelity, State Street, ARK Investment Management, BlackRock, Vanguard Group.

07

Similar stocks